Ionis Pharmaceuticals (IONS) FCF Margin (2009 - 2026)
Ionis Pharmaceuticals' quarterly FCF Margin came in at 331.01% in Q1 2026, down 20689.0% year-on-year from N/an in Q1 2025, and down 323.29% quarter-over-quarter from 78.2% in Q4 2025.
Ionis Pharmaceuticals has reported FCF Margin for 18 years, with the latest figure at 331.01% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 20689.0% year-over-year to 331.01%; the trailing twelve-month figure through Mar 2026 stood at 159.71% (down 8231.0% YoY), and the FY2025 full-year result was 33.91%, up 4355.0% from the prior year.
- FCF Margin for Q1 2026 stood at 331.01%, down from 78.2% in the prior quarter.
- The five-year high for FCF Margin was 6951.65% in Q2 2025, with the low at 331.01% in Q1 2026.
- Average FCF Margin over 5 years is 327.59%, with a median of 77.09% recorded in 2023.
- Year-over-year, FCF Margin surged 700764 bps in 2025 and plunged 20689 bps in 2026.
- Tracing IONS's FCF Margin over 5 years: stood at 134.53% in 2022, then soared by 113 bps to 17.66% in 2023, then plunged by 454 bps to 62.51% in 2024, then retreated by 25 bps to 78.2% in 2025, then sank by 323 bps to 331.01% in 2026.
- The last three FCF Margin figures came in at 331.01% (Q1 2026), 78.2% (Q4 2025), and 87.23% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.17% |
| 10 | Ionis Pharmaceuticals | 12.61 Bn | 10.69 Bn | 243.11 Mn | -331.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -331.01% |
| Dec 31, 2025 | -78.20% |
| Sep 30, 2025 | -87.23% |
| Jun 30, 2025 | 6,951.65% |
| Mar 31, 2025 | -124.12% |
| Dec 31, 2024 | -62.51% |
| Sep 30, 2024 | -92.70% |
| Jun 30, 2024 | -55.99% |
| Mar 31, 2024 | -129.23% |
| Dec 31, 2023 | 17.66% |
| Sep 30, 2023 | -77.09% |
| Jun 30, 2023 | -58.05% |
| Mar 31, 2023 | -110.68% |
| Dec 31, 2022 | -134.53% |
| Sep 30, 2022 | -18.76% |
| Jun 30, 2022 | -16.02% |
| Mar 31, 2022 | -24.21% |
| Dec 31, 2021 | 45.72% |
| Sep 30, 2021 | -44.25% |
| Jun 30, 2021 | -53.29% |
| Mar 31, 2021 | -50.56% |
| Dec 31, 2020 | 225.31% |
| Sep 30, 2020 | -23.25% |
| Jun 30, 2020 | -356.44% |
| Mar 31, 2020 | -6.37% |
| Dec 31, 2019 | 600.17% |
| Sep 30, 2019 | -114.82% |
| Jun 30, 2019 | -518.75% |
| Mar 31, 2019 | 69.65% |
| Dec 31, 2018 | 301.42% |
| Sep 30, 2018 | -206.23% |
| Jun 30, 2018 | 419.21% |
| Mar 31, 2018 | 36.07% |
| Dec 31, 2017 | 26.98% |
| Sep 30, 2017 | 9.86% |
| Jun 30, 2017 | -3.43% |
| Mar 31, 2017 | 103.13% |
| Dec 31, 2016 | -173.28% |
| Sep 30, 2016 | 20.95% |
| Jun 30, 2016 | -94.67% |
| Mar 31, 2016 | -207.18% |
| Dec 31, 2015 | -77.34% |
| Sep 30, 2015 | 71.00% |
| Jun 30, 2015 | 68.14% |
| Mar 31, 2015 | -69.83% |
| Dec 31, 2014 | 79.11% |
| Sep 30, 2014 | 2.44% |
| Jun 30, 2014 | -62.57% |
| Mar 31, 2014 | -119.78% |
| Dec 31, 2013 | -35.34% |
| Sep 30, 2013 | 276.87% |
| Jun 30, 2013 | 194.53% |
| Mar 31, 2013 | -24.90% |
| Dec 31, 2012 | 382.68% |
| Sep 30, 2012 | -215.84% |
| Jun 30, 2012 | -7.03% |
| Mar 31, 2012 | -29.37% |
| Dec 31, 2011 | -74.10% |
| Sep 30, 2011 | -126.11% |
| Jun 30, 2011 | -119.18% |
| Mar 31, 2011 | -200.59% |
| Dec 31, 2010 | -98.41% |
| Sep 30, 2010 | -77.82% |
| Jun 30, 2010 | 17.64% |
| Mar 31, 2010 | -109.27% |
| Dec 31, 2009 | -102.64% |
| Sep 30, 2009 | -125.89% |